Roche said that results from drug trials in three different therapies may offer a better future to women with early and very advanced breast cancer.

Roche will present results on all three drugs at the San Antonio Breast Cancer Symposium in the next few days.

The drug maker said five-year follow up data from its two Herceptin studies into early breast cancer have already shown efficacy in patients when adding 12 months of the drug to standard therapy.

It will also present data from its Avastin RIBBON-2 study as a first-line treatment for women with advanced breast cancer.

In addition, it will release results from a Phase II study into the use of trastuzumab-DM1 for very advanced breast cancer.